Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting
TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that new preclinical data from its STING agonist program will be presented at the 34th annual meeting of the Society for Immunotherapy of Cancer (SITC). The meeting will be held November 6-10 in National Harbor, MD. The poster presentation will highlight the anti-tumor activity of TTI-10001, a novel small molecule STING agonist, when delivered intravenously or orally. Details of the presentation are listed below.
Title: “TTI-10001, a next generation small molecule STING agonist, demonstrates potent anti-tumor activity in mice following intravenous or oral administration”Presenter: Bob Uger, Ph.D., Chief Scientific Officer, Trillium Therapeutics Inc.Date and Time: November 9, 2019 from 8:00 a.m. - 8:30 p.m. ETLocation: Gaylord National Hotel & Convention CenterAbstract Number: P668
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system.
Contact and Investor Relations:James ParsonsChief Financial OfficerTrillium Therapeutics Inc. 416-595-0627 email@example.com